Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was CMO and a member of the board at fellow cancer company CytomX Therapeutics Inc. (NASDAQ:CTMX).

Computational chemistry play Nimbus Therapeutics Inc. hired Scott Edmondson as SVP and head of chemistry. Edmondson was director and head of Boston oncology chemistry at AstraZeneca plc (LSE:AZN; NYSE:AZN)...